TY - JOUR
T1 - Treatment of psoriasis. Part 2. Systemic therapies
AU - Lebwohl, Mark
AU - Ali, Suad
PY - 2001/11
Y1 - 2001/11
N2 - The array of systemic medications used in the treatment of psoriasis is rapidly expanding. In the United States, methotrexate, retinoids, and cyclosporine are the only systemic drugs approved by the Food and Drug Administration for the treatment of psoriasis. Monitoring and dosage recommendations for these medications are reviewed. Other drugs that are currently available include tacrolimus, mycophenolate mofetil, hydroxyurea, 6-thioguanine, and sulfasalazine. Experience with these drugs is summarized, and dosage and monitoring recommendations in published literature are presented. Combinations of different treatments are addressed and investigational therapies that are in development are reviewed.
AB - The array of systemic medications used in the treatment of psoriasis is rapidly expanding. In the United States, methotrexate, retinoids, and cyclosporine are the only systemic drugs approved by the Food and Drug Administration for the treatment of psoriasis. Monitoring and dosage recommendations for these medications are reviewed. Other drugs that are currently available include tacrolimus, mycophenolate mofetil, hydroxyurea, 6-thioguanine, and sulfasalazine. Experience with these drugs is summarized, and dosage and monitoring recommendations in published literature are presented. Combinations of different treatments are addressed and investigational therapies that are in development are reviewed.
UR - http://www.scopus.com/inward/record.url?scp=0034753878&partnerID=8YFLogxK
U2 - 10.1067/mjd.2001.117047
DO - 10.1067/mjd.2001.117047
M3 - Article
C2 - 11606913
AN - SCOPUS:0034753878
SN - 0190-9622
VL - 45
SP - 649
EP - 664
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 5
ER -